Biomarker profiles in late‐life depression and Alzheimer’s disease across and beyond the A/T/N framework: A scoping review

by Clinical Neuropsychologist Online | Wednesday, October 21, 2026 | Dementia

Abstract Depression and Alzheimer’s disease (AD) frequently overlap clinically, and depressive symptoms may signal major depressive disorder, a risk factor for AD, or an early manifestation of neurodegeneration. This scoping review mapped biomarker evidence...

Direction‐specific biomarker profiles and clinical significance of plasma p‐tau217/amyloid PET discordance in cognitively normal adults

by Clinical Neuropsychologist Online | Tuesday, October 20, 2026 | Dementia

Abstract INTRODUCTION Plasma phosphorylated tau (p-tau)217 is increasingly used to triage amyloid testing, but the biological and clinical meaning of discordant plasma p-tau217 and amyloid positron emission tomography (PET) results in cognitively normal adults remains...

H3K9me3 inhibition reverses Alzheimer’s progression by restoring synaptic and immune proteostasis across the brain–retina axis

by Clinical Neuropsychologist Online | Tuesday, October 20, 2026 | Dementia

Abstract INTRODUCTION Epigenetic dysregulation is increasingly linked to aging and neurodegeneration, yet its contribution to retinal and brain pathology in Alzheimer’s disease (AD) remains unclear. METHODS We quantified the repressive epigenetic mark histone H3...

Why diabetes matters in dementia studies: Failure to account for diabetes status masks regional mitochondrial DNA copy number changes in human hippocampus, amygdala, and cerebellum in Alzheimer’s disease

by Clinical Neuropsychologist Online | Tuesday, October 20, 2026 | Dementia

ABSTRACT INTRODUCTION Diabetes is a major risk factor for Alzheimer’s disease (AD), and both diseases involve mitochondrial dysfunction. Changes in mitochondrial DNA (mtDNA) can influence energy metabolism, cellular signaling, and epigenetic programming, thereby...

Analysis of dementia strategic plans in US states

by Clinical Neuropsychologist Online | Monday, October 19, 2026 | Dementia

Abstract State dementia strategic plans provide policy and practice recommendations to reduce the risk, progression, and impact of dementia. Yet there is little systematic understanding of the contents of state plans nor how they aim to influence dementia strategy....

Integration of neuroimaging signatures of aging and Alzheimer’s with fluid biomarkers

by Clinical Neuropsychologist Online | Saturday, October 17, 2026 | Dementia

Abstract INTRODUCTION Machine learning algorithms applied to neuroimaging may aid diagnosis and disease monitoring. This study aimed to derive neuroimaging signatures of brain aging (Spatial Pattern of Atrophy for Recognition–Brain Age [SPARE-BA]) and...